This report asks which pharma companies are ready for diagnostic integration and draws on benchmarking and financial risk assessment. Its analyses of 23 companies, plus therapies on the market and in the pipeline, provide a 360° view of diagnostic-dependent therapy assets. It features big data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of precision medicine beyond molecular testing and makes considered predictions for the developing industry.
Pharma Readiness for Diagnostic Integration 2017
14 March, 2017